Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-12-10

FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XOFIGO (Radium Ra-223 dichloride) submitted by Bayer HealthCare Pharmaceuticals Inc., marking regulatory approva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xofigo (radium-223 dichloride)

Snippet

SUPPL AP for XOFIGO (RADIUM RA 223 DICHLORIDE)